SilvaL.S.B., DuarteT.L., HojoI.H.R. and FonsecaL. de O.L. 2024. An analysis of the benefits of SGLT2 inhibitors in the progression of chronic kidney disease beyond type 2 diabetes. Revista Eletrônica Acervo Médico. 24, (Aug. 2024), e16309. DOI:https://doi.org/10.25248/reamed.e16309.2024.